With MOR103 (out-licensed to GlaxoSmithKline) and MOR202 (partnered with Celgene), MorphoSys has shown its ability to take proprietary products from target discovery into clinical development and on to significant licensing agreements. In the case of MOR202, MorphoSys has secured the right to co-promote the compound together with Celgene in Europe. We intend to develop our wholly-owned drug candidates further, to build on the great potential of MOR202 with Celgene and to invest in other attractive opportunities, including in-licensing and co-development programs.
Our most advanced wholly-owned proprietary compound is MOR208, a monoclonal antibody against CD19 that is being developed for B-cell malignancies and autoimmune diseases. The program, which we in-licensed at IND-stage mid-2010, is currently in phase 2 clinical development in B-ALL, CLL and NHL.